Fibrous Dysplasia Market Information: By Diagnosis (X-Rays, CT Scans, MRI, Bone Scan, Biopsy), Treatment (Medication (Bisphosphonates, Intravenous Pamidronate), Surgical), End User (Hospitals & Clinics, Research Centers) - Forecast Till 2030

Fibrous Dysplasia Market Scenario

The fibrous dysplasia market is projected to reach USD 17,852.74 Million by 2030 at 9.70% CAGR during the forecast period 2022-2030.Fibrous dysplasia is a rare and chronic bone disorder in which fibrous tissue develops in place of normal bone, weakens the affected bone, and deform or fracture it. As per reports from The Johns Hopkins University, the exact cause of fibrous dysplasia is unknown, but it is believed to be due to a chemical irregularity in a specific bone protein. This bone protein abnormality may arise due to a gene mutation present at birth, although it is not known to be an inherited disorder.

It often results in uneven growth of bones, pain, brittle bones, and bone deformity. In fibrous dysplasia, the most commonly affected bones includes femur (thighbone), tibia (shin bone), ribs, skull, facial bones, humerus (the bone of the upper arm), pelvis, vertebrae in the spine (less often).

The fibrous dysplasia market growth is majorly attributed to the increasing prevalence of the bone disorders. Moreover, some cases of fibrous dysplasia leads to cancer, which is likely to drive the market growth.

Currently, no cure is available for fibrous dysplasia. However, present treatment methods helps to prevent complications, such as recurrent bone fractures to help make the condition less severe.

According to reports from International Osteoporosis Foundation, Each year an estimated 1.5 million individuals suffer a fracture due to bone disease. The risk of a fracture increases with age and is more in women. Furthermore, globalization in healthcare has increased the market growth. Established market players in the developed countries leads the globalization by pushing new products and services into developing countries and emerging economies.

However, high cost of the current treatment methods and lack of alternative methods for the treatment of fibrous dysplasia may slow the market growth during the forecast period.

Intended Audience

• Pharmaceutical Companies


• Research and Development (R&D) Companies


• Government Research Institute


• Academic Institutes and Universities


• Medical Research Laboratories


• Market Research and Consulting Service Providers


• Potential Investors

Sources: Annual reports, Press release, White paper, Company presentation 

Segmentations

The fibrous dysplasia market is segmented on the basis by diagnosis, by treatment, and by end user.

On the basis of diagnosis, fibrous dysplasia market is segmented into X-rays, CT scans, MRI, bone scan, biopsy, and others.  

On the basis of treatment, fibrous dysplasia market is segmented into medications, surgical, and others. The medications is further segmented into bisphosphonates, intravenous (IV) pamidronate, calcitonin, raloxifene, and others

On the basis of the end user, fibrous dysplasia market is segmented into hospitals & clinics, research centers, and others.

Regional Analysis

The Americas dominate the fibrous dysplasia market owing to well-developed technology, increasing patient with bone disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the fibrous dysplasia market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period.   

Asia Pacific is the fastest growing market owing to the presence of rapidly developing healthcare technology, increasing patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries such as India is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead to the use of advanced equipment, which, in turn, may increase the market growth of the fibrous dysplasia in the region.   

On the other hand, the Middle East & Africa holds the least share of the fibrous dysplasia market due to limited screening, ignorance of diseases, and poor access to treatment, especially, in African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. 

Key Players

Some of key the players in the fibrous dysplasia market are Novartis AG, Pfizer Inc, Amgen Inc, AVEO Pharmaceuticals Inc, Bayer AG, Bellicum Pharmaceuticals Inc, MediaPharma srl, Merck & Co., Inc, Merrimack Pharmaceuticals Inc, Oncolys BioPharma Inc, United Therapeutics Corp and others.

Research Methodology

Sources: Annual reports, Press release, White paper, and Company presentation